Johnson & Johnson Q3-2025
Health Care · Pharmaceuticals
Operator Signal: TAILWIND
JNJ is firing on both cylinders. Innovative Medicine grew 5.3% operationally with blockbuster oncology and immunology franchises offsetting STELARA biosimilar erosion. MedTech grew 5.6% operationally driven by electrophysiology and cardiovascular. They raised full-year sales guidance from $93.4B to $93.7B midpoint.
If you're building in healthcare or selling into hospital systems, JNJ's accelerating MedTech spend — especially in electrophysiology, AI-powered surgical tools like VIRTUGUIDE, and cardiovascular devices — signals strong institutional budgets and appetite for innovation in surgical workflows.
AI Intelligence
◑ DEPLOYINGJNJ has launched a named AI-powered product (VIRTUGUIDE) into production for surgical planning, but AI is not yet a material revenue driver across the portfolio.
Competitor Intelligence
What They Actually Said
“Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline.”
— Joaquin Duato, Chairman and CEOgrowth-signal
“With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation.”
— Joaquin Duato, Chairman and CEOgrowth-signalproduct-launch
“Company increases full year estimated reported sales guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS guidance of $10.85 at the midpoint, absorbing higher tax costs.”
— Company, Press Releaseguidance